Vectron Biosolutions supplies the life science industry with proprietary upstream expression tools and services to enable robust, cost-efficient production of recombinant proteins in E. coli and other bacteria. The company combines experienced researchers, state-of-the-art laboratory facilities, a proprietary technology platform, and management to support biomanufacturers. Its core products focus on increasing titers and improving protein solubility to reduce cost of goods for microbial expression systems. In June 2021 Vectron announced the acquisition of a bacterial secretion platform from T3S Technologies to complement its expression technology. Management describes high-level expression followed by true secretion as a potential paradigm shift expected to become an industry standard. The company also completed a $2.7 million Series A financing led by Dynamk Capital to support growth and platform integration.

Total raised

$3M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2021